Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has reached an agreement with the U.S. government to lower drug prices, expand patient access, and provide a newly approved gene therapy at no cost, aligning with policy priorities outlined by Donald Trump.

The deal, announced Thursday, follows discussions at the White House involving Regeneron co-founders Leonard Schleifer and George Yancopoulos, and addresses pricing, accessibility, and domestic investment commitments.

Pricing Alignment And Direct Access Initiatives

Under the agreement, Regeneron will tie Medicaid drug pricing to benchmarks in other developed countries and align future U.S. medicine prices with those international levels.

The company will also make its cholesterol-lowering drug Praluent (alirocumab) available for direct purchase through TrumpRx.gov at a most-favored-nation price, potentially bypassing traditional distribution channels for eligible patients.

Free Gene Therapy For Rare ...